138 related articles for article (PubMed ID: 38071594)
1. A systematic review of early phase studies for children and young people with relapsed and refractory rhabdomyosarcoma: The REFoRMS-SR project.
Evans C; Shepherd L; Bryan G; Fulbright H; Crowther S; Wakeling S; Stewart A; Stewart C; Chisholm J; Gibson F; Phillips B; Morgan JE
Int J Cancer; 2024 Apr; 154(7):1235-1260. PubMed ID: 38071594
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of combined surgery and brachytherapy approaches for children and young people with relapsed and refractory rhabdomyosarcoma (Local-REFoRMS).
Ballantyne E; Evans C; Shepherd L; Fulbright H; Wakeling S; Phillips B; Morgan JE
Pediatr Blood Cancer; 2024 Jun; 71(6):e30952. PubMed ID: 38566349
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.
Defachelles AS; Bogart E; Casanova M; Merks JHM; Bisogno G; Calareso G; Gallego Melcon S; Gatz SA; Le Deley MC; McHugh K; Probst A; Rocourt N; van Rijn RR; Wheatley K; Minard-Colin V; Chisholm JC
J Clin Oncol; 2021 Sep; 39(27):2979-2990. PubMed ID: 34343032
[TBL] [Abstract][Full Text] [Related]
5. Retrospective Analysis of Outcomes of Patients with Relapsed, Refractory and Metastatic Sarcomas who have received Metronomic Chemotherapy.
Devadas SK; Banavali S
Gulf J Oncolog; 2019 May; 1(30):22-28. PubMed ID: 31242978
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
7. Adolescents and young adults with rhabdomyosarcoma treated in the European paediatric Soft tissue sarcoma Study Group (EpSSG) protocols: a cohort study.
Ferrari A; Chisholm JC; Jenney M; Minard-Colin V; Orbach D; Casanova M; Guillen G; Glosli H; van Rijn RR; Schoot RA; Cameron AL; Rogers T; Alaggio R; Ben-Arush M; Mandeville HC; Devalck C; Defachelles AS; Coppadoro B; Bisogno G; Merks JHM
Lancet Child Adolesc Health; 2022 Aug; 6(8):545-554. PubMed ID: 35690071
[TBL] [Abstract][Full Text] [Related]
8. Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
Büyükkapu Bay S; Kebudi R; Görgün O; Zülfikar B; Darendeliler E; Çakır FB
J Oncol Pharm Pract; 2019 Sep; 25(6):1343-1348. PubMed ID: 30080131
[TBL] [Abstract][Full Text] [Related]
9. Metastatic adult-type non-rhabdomyosarcoma soft tissue sarcomas in children and adolescents: A cohort study from the European paediatric Soft tissue sarcoma Study Group.
Ferrari A; Orbach D; Casanova M; van Noesel MM; Berlanga P; Brennan B; Corradini N; Schoot RA; Ramirez-Villar GL; Hjalgrim LL; Alaggio R; Guillen Burrieza G; Safwat A; Cameron AL; van Rijn RR; Minard-Colin V; Zanetti I; Bisogno G; Chisholm JC; Merks JHM
Cancer; 2023 Aug; 129(16):2542-2552. PubMed ID: 37084075
[TBL] [Abstract][Full Text] [Related]
10. Topotecan/carboplatin regimen for refractory/recurrent rhabdomyosarcoma in children: Report from the AIEOP Soft Tissue Sarcoma Committee.
Compostella A; Affinita MC; Casanova M; Milano GM; Scagnellato A; Dall'Igna P; Chiaravalli S; Pierobon M; Manzitti C; Zanetti I; Schiavetti A; Sorbara S; Mura RM; Ruggiero A; Ferrari A; Bisogno G
Tumori; 2019 Apr; 105(2):138-143. PubMed ID: 30131003
[TBL] [Abstract][Full Text] [Related]
11. Relapse after localized rhabdomyosarcoma: Evaluation of the efficacy of second-line chemotherapy.
Winter S; Fasola S; Brisse H; Mosseri V; Orbach D
Pediatr Blood Cancer; 2015 Nov; 62(11):1935-41. PubMed ID: 26150380
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma.
Tansir G; Rastogi S; Kumar A; Barwad A; Mridha AR; Dhamija E; Shamim SA; Bhatnagar S; Bhoriwal S
BMC Cancer; 2023 Jul; 23(1):639. PubMed ID: 37422615
[TBL] [Abstract][Full Text] [Related]
13. Second-line treatment of pediatric patients with relapsed rhabdomyosarcoma adapted to initial risk stratification: Data of the European Soft Tissue Sarcoma Registry (SoTiSaR).
Heinz AT; Ebinger M; Schönstein A; Fuchs J; Timmermann B; Seitz G; Vokuhl C; Münter MW; Pajtler KW; Stegmaier S; von Kalle T; Kratz CP; Rößler J; Ljungman G; Klingebiel T; Koscielniak E; Sparber-Sauer M;
Pediatr Blood Cancer; 2023 Jul; 70(7):e30363. PubMed ID: 37066598
[TBL] [Abstract][Full Text] [Related]
14. A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412.
Davis KL; Fox E; Isikwei E; Reid JM; Liu X; Minard CG; Voss S; Berg SL; Weigel BJ; Mackall CL
Clin Cancer Res; 2022 Dec; 28(23):5088-5097. PubMed ID: 36190525
[TBL] [Abstract][Full Text] [Related]
15. Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A meta-analysis.
Allen-Rhoades W; Lupo PJ; Scheurer ME; Chi YY; Kuttesch JF; Venkatramani R; Meyer WH; Mascarenhas L
Cancer Med; 2023 May; 12(9):10222-10229. PubMed ID: 37016270
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group.
Vassal G; Couanet D; Stockdale E; Geoffray A; Geoerger B; Orbach D; Pichon F; Gentet JC; Picton S; Bergeron C; Cisar L; Assadourian S; Morland B; ;
J Clin Oncol; 2007 Feb; 25(4):356-61. PubMed ID: 17264330
[TBL] [Abstract][Full Text] [Related]
17. Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.
Amoroso L; Castel V; Bisogno G; Casanova M; Marquez-Vega C; Chisholm JC; Doz F; Moreno L; Ruggiero A; Gerber NU; Fagioli F; Hingorani P; Melcón SG; Slepetis R; Chen N; le Bruchec Y; Simcock M; Vassal G
Eur J Cancer; 2020 Aug; 135():89-97. PubMed ID: 32554315
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
Metts JL; Trucco M; Weiser DA; Thompson P; Sandler E; Smith T; Crimella J; Sansil S; Thapa R; Fridley BL; Llosa N; Badgett T; Gorlick R; Reed D; Gill J
Cancer Med; 2023 Feb; 12(4):4270-4281. PubMed ID: 36151773
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
